Cambio de paradigma en el EGFR mutado: desde las primeras mutaciones a las de resistencia - page 5

Osimertinib front-line: PFS

•

RR 77%

•

Median PFS 19.3 mo at 160 mg dose, not yet reached at 80 mg dose

•

Median duration of response not yet reached

(ELCC 16)

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4 6,7,8,9,10,11,12,13,14,15,...35